MapLight Therapeutics, Inc. (MPLT)
13.06
-0.25
(-1.88%)
USD |
NASDAQ |
Sep 02, 16:00
13.05
-0.01
(-0.08%)
After-Hours: 20:00
MapLight Therapeutics Research and Development Expense (Annual) : 138.35M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 138.35M |
| December 31, 2024 | 67.82M |
| Date | Value |
|---|---|
| December 31, 2023 | 49.12M |
| December 31, 2022 | 26.57M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Evommune, Inc. | 74.04M |
| Sarepta Therapeutics, Inc. | 1.493B |
| Cullinan Therapeutics, Inc. | 187.40M |
| Mineralys Therapeutics, Inc. | 132.01M |
| Apogee Therapeutics, Inc. | 214.42M |